Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,379 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Ando Y, Nishiyama H, Shimodaira H, Takano N, Sakaida E, Matsumoto K, Nakanishi K, Sakai H, Tsukamoto S, Komine K, Yasuda Y, Kato T, Fujiwara Y, Koyama T, Kitamura H, Kuwabara T, Yonezawa A, Okumura Y, Yakushijin K, Nozawa K, Goto H, Matsubara T, Hoshino J, Yanagita M; Committee of Clinical Practice Guidelines for the Management of Kidney Disease During Anticancer Drug Therapy 2022. Ando Y, et al. Among authors: kato t. Int J Clin Oncol. 2023 Oct;28(10):1315-1332. doi: 10.1007/s10147-023-02382-2. Epub 2023 Jul 16. Int J Clin Oncol. 2023. PMID: 37453935
The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study.
Kato T, Nagahara A, Kawamura N, Nakata W, Soda T, Matsuzaki K, Hatano K, Kawashima A, Ujike T, Imamura R, Nishimura K, Takada S, Tsujihata M, Yamaguchi S, Takao T, Nishimura K, Nonomura N, Uemura M. Kato T, et al. Int J Clin Oncol. 2021 May;26(5):954-961. doi: 10.1007/s10147-021-01872-5. Epub 2021 Jan 20. Int J Clin Oncol. 2021. PMID: 33471290
Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study.
Kato T, Fujita K, Minami T, Nagahara A, Hyashi Y, Nakata W, Matsuzaki K, Nakano K, Hatano K, Kawashima A, Imamura R, Takada S, Nishimura K, Tsujihata M, Takao T, Nakai Y, Nakayama M, Nishimura K, Uemura M, Uemura H, Nonomura N. Kato T, et al. Int J Clin Oncol. 2022 Oct;27(10):1596-1604. doi: 10.1007/s10147-022-02215-8. Epub 2022 Jul 13. Int J Clin Oncol. 2022. PMID: 35831538
The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.
Oka T, Hatano K, Okuda Y, Yamamoto A, Uemura T, Yamamichi G, Tomiyama E, Ishizuya Y, Yamamoto Y, Kato T, Kawashima A, Fujita K, Nonomura N. Oka T, et al. Among authors: kato t. Int J Clin Oncol. 2023 Mar;28(3):427-435. doi: 10.1007/s10147-022-02288-5. Epub 2022 Dec 29. Int J Clin Oncol. 2023. PMID: 36580184
Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.
Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N. Yanagita M, et al. Among authors: kato t. Clin Exp Nephrol. 2024 Feb;28(2):85-122. doi: 10.1007/s10157-023-02415-0. Epub 2023 Oct 25. Clin Exp Nephrol. 2024. PMID: 37878114 Free PMC article. No abstract available.
Correction to: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.
Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N. Yanagita M, et al. Among authors: kato t. Clin Exp Nephrol. 2024 Feb;28(2):123-124. doi: 10.1007/s10157-023-02436-9. Clin Exp Nephrol. 2024. PMID: 38070021 Free PMC article. No abstract available.
Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma.
Kawashima A, Uemura M, Kato T, Ujike T, Nagahara A, Fujita K, Imamura R, Yamanaka Y, Tomiyama E, Tanigawa G, Miyagawa Y, Yoshioka T, Miyake O, Nonomura N. Kawashima A, et al. Among authors: kato t. Int J Clin Oncol. 2019 Jan;24(1):78-86. doi: 10.1007/s10147-018-1332-1. Epub 2018 Aug 9. Int J Clin Oncol. 2019. PMID: 30094693 Free PMC article.
Novel diagnostic model for bone metastases in renal cell carcinoma patients based on bone scintigraphy analyzed by computer-aided diagnosis software and bone turnover markers.
Ujike T, Uemura M, Kato T, Hatano K, Kawashima A, Nagahara A, Fujita K, Imamura R, Nonomura N. Ujike T, et al. Among authors: kato t. Int J Clin Oncol. 2022 Apr;27(4):774-780. doi: 10.1007/s10147-021-02107-3. Epub 2022 Feb 4. Int J Clin Oncol. 2022. PMID: 35119579 Free PMC article.
12,379 results
You have reached the last available page of results. Please see the User Guide for more information.